Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next?
Ilana SchlamJoshua DowerFilipa C LyncePublished in: Current oncology reports (2024)
There has been a shift towards neoadjuvant systemic therapy for selected patients with HER2-positive and TNBC. Assessing the tumor's response to therapy provides prognostic information and allows individualization of the postoperative treatment for these patients based on the tumor response to neoadjuvant therapy. Patients with TNBC with residual disease after neoadjuvant therapy can be treated with pembrolizumab, capecitabine, or olaparib. Those with HER2-positive disease are treated with adjuvant trastuzumab emtansine. The treatment of early breast cancer has evolved significantly, and patient outcomes continue to improve. As better treatments are developed, we will need biomarkers to determine which patients may benefit from certain therapies to continue to improve outcomes by right-sizing treatments and limiting toxicities.
Keyphrases
- end stage renal disease
- newly diagnosed
- rectal cancer
- locally advanced
- chronic kidney disease
- lymph node
- prognostic factors
- peritoneal dialysis
- clinical trial
- healthcare
- patients undergoing
- early stage
- radiation therapy
- squamous cell carcinoma
- patient reported outcomes
- metastatic breast cancer
- health information
- adipose tissue
- skeletal muscle
- study protocol
- positive breast cancer